ION BIOTECHNOLOGY (USA), INC.
Ion Biotechnology has a family of therapeutic technologies using ions including ionic metals. These ionic technologies are theorized to target cells which do not follow the full Krebs metabolic cycle. This may include cancer cells, bacteria, and other pathogens.
ION BIOTECHNOLOGY (USA), INC.
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2017-01-10
Website Url:
http://www.ionbiotech.com
Total Employee:
1+
Status:
Active
Contact:
(832)628-2212
Email Addresses:
[email protected]
Technology used in webpage:
Amazon Google Apps For Business GoDaddy DNS AWS Global Accelerator WordPress Hosting
Similar Organizations
Sunol Molecular
A development stage biotechnology company with products for cardiovascular, cancer and inflammatory diseases.
Xori Corporation
XORI Corporation develops technology for discovery and development of monoclonal antibodies which are used to treat cancers, immune
Current Employees Featured
Official Site Inspections
http://www.ionbiotech.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ion Biotechnology (USA), Inc."
IO Biotech - Crunchbase Company Profile & Funding
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune …See details»
IO Biotech, Inc. - Governance - Board of Directors
During his career, he was o.a. President of the the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and President of ECCO (European CanCer Organization) from 2008 to 2010, and …See details»
IO Biotech, Inc. - Governance - Executive Management
Dr. Zocca also led DanDrit Biotech A/S, a biotechnology company, as its Chief Executive Officer from July 2007 until December 2010. Dr. Zocca currently serves on the board of directors for Dansk Biotek, a Danish biotechnology trade …See details»
IO Biotech - LinkedIn
IO Biotech is a clinical-stage biopharmaceutical company pioneering the first-in-class investigational dual-action immune-modulating cancer vaccine with the goal of becoming the backbone of ...See details»
IO Biotech, Inc. - Governance - Board of Directors - Person Details
During his career, he was o.a. President of the the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and President of ECCO (European CanCer …See details»
IO Biotech, Inc. (IOBT) Company Profile & Facts - Yahoo Finance
See the company profile for IO Biotech, Inc. (IOBT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
IO Biotech - Craft
Oct 2, 2024 IO Biotech is a clinical-stage biotech company developing immune-modulating cancer therapies. It utilizes the T-win technology platform and develops IO102-IO103 designed …See details»
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) - IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer …See details»
IO Biotech Announces Positive Results from Phase 2 Trial of IO102 …
NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic …See details»
Science - IO Biotech
Nov 7, 2024 During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from 2008 to 2010. He is currently President of the …See details»
IO Biotech Announces New Head and Neck Cohort Data Accepted …
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...See details»
IO Biotech Announces Participation in Upcoming Investor …
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on …See details»
IO Biotech, Inc. - IO Biotech Strengthens Executive Management …
Jul 18, 2023 Over the past 6 years, IO Biotech has grown from a 10-person organization to a publicly traded, international company with a pipeline of clinical programs and more than 60 …See details»
IO Biotech Announces Positive Results from Phase 2 Trial of
Sep 14, 2024 [email protected]. Media Julie Funesti Salutem 917-498-1967 [email protected] ...See details»
T-win - IO Biotech
During his career, he chaired the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and ECCO (European CanCer Organization) from 2008 to 2010. …See details»
IO Biotech, Inc. - IO Biotech Reports First Quarter 2024 Financial ...
May 14, 2024 Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational …See details»
A randomized Phase 2 trial of the IO102-IO103 (IDO and PD-L1)
Title: 1201861 IOB-032_ASCO 2024_Trials in Progress Poster_RGB_ePoster_HR PDF Author: Lara Wilson Created Date: 5/20/2024 11:39:16 AMSee details»
Programs - IO Biotech
IO112 is our wholly owned, novel T-win® vaccine candidate that is designed to activate and expand T cells specific for arginase-1. Arginase-1 is highly expressed by difficult-to-treat …See details»
IO Biotech, Inc. - IO Biotech Announces an Invited Oral …
Nov 9, 2022 - Preclinical data showing the rationale for two new pipeline candidates targeting the immunosuppressive effects of Arginase-1 (ARG1) and Transforming Growth Factor Beta 1 …See details»